Interpace Biosciences (IDXG)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	2.11 mm	2.11 mm	2.11 mm	2.11 mm	2.11 mm	2.11 mm
Cash burn (monthly)	233.00 k	247.17 k	(no burn)	(no burn)	(no burn)	(no burn)
Cash used (since last report)	656.26 k	696.16 k	n/a	n/a	n/a	n/a
Cash remaining	1.46 mm	1.42 mm	n/a	n/a	n/a	n/a
Runway (months of cash)	6.3	5.7	n/a	n/a	n/a	n/a

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2021

IDXG institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	0	0
Opened positions	0	0
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0.00	0.00
Total shares	0.00	0.00
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

IDXG insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
11 Oct 24	Ampersand 2018 Limited Partnership	Series C Convertible Preferred Stock Common Stock	Grant	Acquire A	Yes	No	2.02	28,000	56.56 k	28,000
11 Oct 24	Ampersand 2018 Limited Partnership	Series B Convertible Preferred Stock Common Stock	Sale back to company	Acquire D	Yes	No	6	28,000	168.00 k	0
11 Oct 24	1315 Capital II	Series C Convertible Preferred Stock Common Stock	Grant	Acquire A	Yes	No	2.02	19,000	38.38 k	19,000
11 Oct 24	1315 Capital II	Series B Convertible Preferred Stock Common Stock	Sale back to company	Acquire D	Yes	No	6	19,000	114.00 k	0
1 Feb 24	Christopher McCarthy	Common Stock	Grant	Acquire A	No	No	0	10,000	0.00	45,644
31 Jul 23	Christopher McCarthy	Common Stock	Grant	Acquire A	No	No	0	25,000	0.00	35,644

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Press releases

From Benzinga Pro

Interpace Biosciences Announces Record Third Quarter 2024 Financial and Business Results

4 Nov 24

●Q3 Revenue of $12.3 million; a $3.2M and 35% increase year-over-year ●Q3 Test volume up 26% year over year to record levels ●Q3 Cash collections of $11.3M; a $1.4M and 15% increase year-over-year ●Q3 Volume, Revenue,

Interpace Biosciences Announces Capital Restructuring of Its Preferred Stock as a First Step Toward Seeking an Uplisting of Its Common Stock to Nasdaq

15 Oct 24

PARSIPPANY, NJ, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced that its Series B Preferred Stock investors, Ampersand Capital Partners and 1315